US stock futures dip as Nvidia earnings spark little cheer
FORT WORTH, Texas - Sanara MedTech Inc. (NASDAQ:SMTI), a $256 million market cap healthcare company with impressive gross profit margins of 91%, announced Monday the launch of a wound care provider pilot program through its subsidiary, Tissue Health Plus, LLC (THP).
The program, which began in the second quarter of 2025, partners with a wound care provider group that delivers at-home care for chronic wounds across six states. The initiative aims to collect real-world evidence on the use of THP’s technology platform. Despite strong revenue growth of 35% over the last twelve months, the company is yet to achieve profitability, according to InvestingPro data.
"The THP technology platform will serve as the provider group’s Wound Care Operating System," said Sam Muppalla, President and CEO of THP. The platform includes Co-Pilot software to standardize patient encounter planning and treatment interventions while ensuring compliance with reimbursement requirements.
According to the company, practitioners are utilizing the platform’s two-way integration with the group’s electronic medical record to streamline post-encounter administrative processes.
Ron Nixon, Sanara’s Executive Chairman and CEO, called the pilot program "an important milestone" in the company’s THP strategy. Nixon added that Sanara is focusing on engaging with payers, with the goal of launching a THP pilot program with a payer during the second half of 2025.
The company stated that it is also seeking potential financial partners to invest in the execution of its THP strategy.
Sanara MedTech plans to share a full company update during its earnings call scheduled for August 13, 2025. Wall Street analysts maintain a bullish outlook, with price targets ranging from $45 to $53. For deeper insights into SMTI’s financial health and growth prospects, investors can access the comprehensive Pro Research Report available on InvestingPro, which covers over 1,400 US stocks.
The information in this article is based on a company press release statement.
In other recent news, Sanara MedTech reported its first-quarter financial results for 2025, showcasing a 26% year-over-year increase in revenue, reaching $23.4 million. Despite this growth, the company recorded a net loss of $3.5 million, or $0.41 per share, which was higher than anticipated. This earnings miss, where revenue fell short of the $24.1 million forecast, has raised concerns among investors about the company’s ability to meet future expectations. On the analyst front, H.C. Wainwright raised its price target for Sanara MedTech to $53, up from $51, while maintaining a Buy rating, indicating confidence in the company’s growth potential. Meanwhile, Cantor Fitzgerald reaffirmed its Overweight rating with a $45 price target, underscoring its belief in the company’s market position. Sanara MedTech has expanded its market reach, with its products now sold in over 1,300 facilities and approved for sale in more than 4,000 hospitals and ambulatory surgery centers. The company has also seen notable demand for its soft tissue repair products, particularly CellerateRX Surgical Activated Collagen, contributing to its revenue growth. Additionally, Sanara MedTech is focusing on expanding its distributor network and increasing penetration in existing healthcare facilities to drive further growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.